Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype

Journal of Medical Microbiology

Volumn 63, Issue , 2014, Pages 1260-1273

  Yacyshyn, Mary B ^a   Reddy, Tara N ^a   Plageman, Lauren R ^a   Wu, Jiang ^a   Hollar, Amy R ^a   Yacyshyn, Bruce R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; CHEMISTRY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MONONUCLEAR CELL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECURRENCE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 84907285774     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.075382-0     Document Type: Article

References (43)

1. Adlerberth, I., Huang, H., Lindberg, E., Åberg, N., Hesselmar, B., Saalman, R., Nord, C. E., Wold, A. E. & Weintraub, A. (2014). Toxinproducing Clostridium difficile strains as long-term gut colonizers in healthy infants. J Clin Microbiol 52, 173-179.
2. Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T. & other authors (2011). Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337-341.
3. Ausiello, C. M., Cerquetti, M., Fedele, G., Spensieri, F., Palazzo, R., Nasso, M., Frezza, S. & Mastrantonio, P. (2006). Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect 8, 2640-2646.
4. Berthelot, J. M., Jamin, C., Amrouche, K., Le Goff, B., Maugars, Y. & Youinou, P. (2013). Regulatory B cells play a key role in immune system balance. Joint Bone Spine 80, 18-22.
5. Bianco, M., Fedele, G., Quattrini, A., Spigaglia, P., Barbanti, F., Mastrantonio, P. & Ausiello, C.M. (2011). Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. J Med Microbiol 60, 1162-1167.
6. Bulusu, M., Narayan, S., Shetler, K. & Triadafilopoulos, G. (2000). Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 95, 3137-3141.
7. CDC (2013). Antibiotic resistance threats in the United States. Available at: http://www.cdc.gov/drugresistance/threat-report-2013 [accessed 3 December 2013].
8. Chiba, T. & Seno, H. (2011). Indigenous Clostridium species regulate systemic immune responses by induction of colonic regulatory T cells. Gastroenterology 141, 1114-1116.
9. Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F. & Annunziato, F. (2014). T helper cells plasticity in inflammation. Cytometry A 85, 36-42.
10. El Feghaly, R. E., Stauber, J. L., Deych, E., Gonzalez, C., Tarr, P. I. & Haslam, D. B. (2013a). Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56, 1713-1721.
11. El Feghaly, R. E., Stauber, J. L., Tarr, P. I. & Haslam, D. B. (2013b). Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr 163, 1697-1704, e2.
12. Farrar, M. A. & Schreiber, R. D. (1993). The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11, 571-611.
13. Foglia, G., Shah, S., Luxemburger, C. & Pietrobon, P. J. F. (2012). Clostridium difficile: development of a novel candidate vaccine. Vaccine 30, 4307-4309.
14. Gaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M. & other authors (2009). The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31, 677-689.
15. Gopal, R., Rangel-Moreno, J., Fallert Junecko, B. A., Mallon, D. J., Chen, K., Pociask, D. A., Connell, T. D., Reinhart, T. A., Alcorn, J. F. & other authors (2014). Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol 184, 55-63.
16. Ishida, Y., Maegawa, T., Kondo, T., Kimura, A., Iwakura, Y., Nakamura, S. & Mukaida, N. (2004). Essential involvement of IFN-γ in Clostridium difficile toxin A-induced enteritis. J Immunol 172, 3018-3025.
17. Jafari, N. V., Kuehne, S. A., Bryant, C. E., Elawad, M., Wren, B. W., Minton, N. P., Allan, E. & Bajaj-Elliott, M. (2013). Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s). PLoS ONE 8, e69846.
18. Kelly, C. P. (2012). Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18 (Suppl. 6), 21- 27.
19. Kelly, C. P. & Kyne, L. (2011). The host immune response to Clostridium difficile. J Med Microbiol 60, 1070-1079.
20. Koon, H. W., Shih, D. Q., Hing, T. C., Yoo, J. H., Ho, S., Chen, X., Kelly, C. P., Targan, S. R. & Pothoulakis, C. (2013). Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother 57, 3214-3223.
21. Lavergne, V., Beauséjour, Y., Pichette, G., Ghannoum, M. & Su, S. H. (2013). Lymphopenia as a novel marker of Clostridium difficile infection recurrence. J Infect 66, 129-135.
22. Lo Vecchio, A. & Zacur, G. M. (2012). Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28, 1-9.
23. Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Jr, Leney, M. & other authors (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362, 197-205.
24. Madan, R. & Petri, W. A., Jr (2012). Immune responses to Clostridium difficile infection. Trends Mol Med 18, 658-666.
25. Mahida, Y. R., Galvin, A., Makh, S., Hyde, S., Sanfilippo, L., Borriello, S. P. & Sewell, H. F. (1998). Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun 66, 5462-5469.
26. Malmhäll, C., Bossios, A., Rådinger, M., Sjöstrand, M., Lu, Y., Lundbäck, B. & Lötvall, J. (2012). Immunophenotyping of circulating T helper cells argues for multiple functions and plasticity of T cells in vivo in humans possible role in asthma. PLoS ONE 7, e40012.
27. Mao, J. H., Chen, Z. M., Tang, Y. M., Liang, L., Du, L. Z. & Zhang, Y. (2004). [Regulation of CD3, CD4 and CD8 expressions on PMAactivated human peripheral T cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban 33, 155-159 (in Chinese).
28. Martin, J., Mawer, D. & Wilcox, M. H. (2013). Clostridium difficile: biological therapies. Curr Opin Infect Dis 26, 454-460.
29. Monaghan, T. M., Robins, A., Knox, A., Sewell, H. F. & Mahida, Y. R. (2013). Circulating antibody and memory B-cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PLoS ONE 8, e74452.
30. Noh, J., Choi, W. S., Noh, G. & Lee, J. H. (2010). Presence of Foxp3- expressing CD19(+)CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg). Immune Netw 10, 247-249.
31. Omoyinmi, E., Hamaoui, R., Pesenacker, A., Nistala, K., Moncrieffe, H., Ursu, S., Wedderburn, L. R. & Woo, P. (2012). Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 51, 1881-1886.
32. Péchiné, S., Janoir, C., Boureau, H., Gleizes, A., Tsapis, N., Hoys, S., Fattal, E. & Collignon, A. (2007). Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25, 3946-3954.
33. Pelchen-Matthews, A., Parsons, I. J. & Marsh, M. (1993). Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 178, 1209-1222.
34. Planche, T. (2013). Clostridium difficile. Medicine 41, 654-657.
35. Rousseau, C., Poilane, I., De Pontual, L., Maherault, A. C., Le Monnier, A. & Collignon, A. (2012). Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 55, 1209-1215.
36. Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., Jr & Infectious Diseases Society of America (2008). The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46, 155- 164.
37. Thaiss, C. A., Levy, M., Suez, J. & Elinav, E. (2014). The interplay between the innate immune system and the microbiota. Curr Opin Immunol 26, 41-48.
38. Ueno, A., Jijon, H., Chan, R., Ford, K., Hirota, C., Kaplan, G. G., Beck, P. L., Iacucci, M., Fort Gasia, M. & other authors (2013). Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 19, 2522-2534.
39. Vadasz, Z., Haj, T., Kessel, A. & Toubi, E. (2013). B-regulatory cells in autoimmunity and immune mediated inflammation. FEBS Lett 587, 2074-2078.
40. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M. & other authors (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368, 407-415.
41. Villano, S. A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E. & Gerding, D. N. (2012). Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56, 5224-5229.
42. Wu, D., Joyee, A. G., Nandagopal, S., Lopez, M., Ma, X., Berry, J. & Lin, F. (2013). Effects of Clostridium difficile toxin A and B on human T lymphocyte migration. Toxins (Basel) 5, 926-938.
43. Yacyshyn, M. B. & Yacyshyn, B. (2013). The role of gut inflammation in recurrent Clostridium difficile-associated disease. Clin Infect Dis 56, 1722-1723.